Cisatracurium besylate injection has a market value of approximately $14 million in the 12 months ending January 2025, per ...

Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the treatment of ...

Health Canada approves Hikma Pharma’s Kloxxado nasal spray 8 mg for treatment of known or suspected opioid overdose: London Monday, March 24, 2025, 13:00 Hrs [IST] Hikma Pharmac ...

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the ...